Literature DB >> 22069312

Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes.

Marta Busnelli1, Aude Saulière, Maurice Manning, Michel Bouvier, Celine Galés, Bice Chini.   

Abstract

We used a bioluminescence resonance energy transfer biosensor to screen for functional selective ligands of the human oxytocin (OT) receptor. We demonstrated that OT promoted the direct engagement and activation of G(q) and all the G(i/o) subtypes at the OT receptor. Other peptidic analogues, chosen because of specific substitutions in key OT structural/functional residues, all showed biased activation of G protein subtypes. No ligand, except OT, activated G(oA) or G(oB), and, with only one exception, all of the peptides that activated G(q) also activated G(i2) and G(i3) but not G(i1), G(oA), or G(oB), indicating a strong bias toward these subunits. Two peptides (DNalOVT and atosiban) activated only G(i1) or G(i3), failed to recruit β-arrestins, and did not induce receptor internalization, providing the first clear examples of ligands differentiating individual G(i/o) family members. Both analogs inhibited cell proliferation, showing that a single G(i) subtype-mediated pathway is sufficient to prompt this physiological response. These analogs represent unique tools for examining the contribution of G(i/o) members in complex biological responses and open the way to the development of drugs with peculiar selectivity profiles. This is of particular relevance because OT has been shown to improve symptoms in neurodevelopmental and psychiatric disorders characterized by abnormal social behaviors, such as autism. Functional selective ligands, activating a specific G protein signaling pathway, may possess a higher efficacy and specificity on OT-based therapeutics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22069312      PMCID: PMC3281696          DOI: 10.1074/jbc.M111.277178

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Real-time monitoring of receptor and G-protein interactions in living cells.

Authors:  Céline Galés; R Victor Rebois; Mireille Hogue; Phan Trieu; Andreas Breit; Terence E Hébert; Michel Bouvier
Journal:  Nat Methods       Date:  2005-02-17       Impact factor: 28.547

Review 2.  Seven-transmembrane receptor signaling through beta-arrestin.

Authors:  Sudha K Shenoy; Robert J Lefkowitz
Journal:  Sci STKE       Date:  2005-11-01

3.  Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.

Authors:  Maurice Manning; Ling Ling Cheng; Stoytcho Stoev; Nga Ching Wo; W Y Chan; Hazel H Szeto; Thierry Durroux; Bernard Mouillac; Claude Barberis
Journal:  J Pept Sci       Date:  2005-10       Impact factor: 1.905

Review 4.  Functional selectivity and classical concepts of quantitative pharmacology.

Authors:  Jonathan D Urban; William P Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; Harel Weinstein; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2006-06-27       Impact factor: 4.030

5.  Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes.

Authors:  Céline Galés; Joost J J Van Durm; Stéphane Schaak; Stéphanie Pontier; Yann Percherancier; Martin Audet; Hervé Paris; Michel Bouvier
Journal:  Nat Struct Mol Biol       Date:  2006-08-13       Impact factor: 15.369

6.  Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output.

Authors:  Andreas Markus Loening; Timothy David Fenn; Anna M Wu; Sanjiv Sam Gambhir
Journal:  Protein Eng Des Sel       Date:  2006-07-20       Impact factor: 1.650

7.  Oxytocin receptors differentially signal via Gq and Gi proteins in pregnant and nonpregnant rat uterine myocytes: implications for myometrial contractility.

Authors:  Xiao-Bo Zhou; Susanne Lutz; Frank Steffens; Michael Korth; Thomas Wieland
Journal:  Mol Endocrinol       Date:  2006-12-14

8.  The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism.

Authors:  Alessandra Reversi; Valeria Rimoldi; Tiziana Marrocco; Paola Cassoni; Giovanni Bussolati; Marco Parenti; Bice Chini
Journal:  J Biol Chem       Date:  2005-02-10       Impact factor: 5.157

9.  An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

Authors:  C E Groer; K Tidgewell; R A Moyer; W W Harding; R B Rothman; T E Prisinzano; L M Bohn
Journal:  Mol Pharmacol       Date:  2006-11-07       Impact factor: 4.436

10.  Internalization and desensitization of the oxytocin receptor is inhibited by Dynamin and clathrin mutants in human embryonic kidney 293 cells.

Authors:  M P Smith; V J Ayad; S J Mundell; C A McArdle; E Kelly; A López Bernal
Journal:  Mol Endocrinol       Date:  2005-09-22
View more
  52 in total

1.  Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues.

Authors:  Yuan Liao; Bin Lu; Qiang Ma; Gang Wu; Xiangru Lai; Jiashu Zang; Ying Shi; Dongxiang Liu; Feng Han; Naiming Zhou
Journal:  J Biol Chem       Date:  2016-02-10       Impact factor: 5.157

2.  β2-Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle--ligand-directed signalling or a reflection of system complexity?

Authors:  Bronwyn A Evans; Dana S Hutchinson; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-09       Impact factor: 3.000

3.  Biased Oxytocinergic Modulation of Midbrain Dopamine Systems.

Authors:  Lei Xiao; Michael F Priest; Jordan Nasenbeny; Ting Lu; Yevgenia Kozorovitskiy
Journal:  Neuron       Date:  2017-06-29       Impact factor: 17.173

4.  Binding Characteristics of Two Oxytocin Variants and Vasopressin at Oxytocin Receptors from Four Primate Species with Different Social Behavior Patterns.

Authors:  Jack H Taylor; Nancy A Schulte; Jeffrey A French; Myron L Toews
Journal:  J Pharmacol Exp Ther       Date:  2018-08-01       Impact factor: 4.030

5.  A Comparison of the Ability of Leu8- and Pro8-Oxytocin to Regulate Intracellular Ca2+ and Ca2+-Activated K+ Channels at Human and Marmoset Oxytocin Receptors.

Authors:  Marsha L Pierce; Suneet Mehrotra; Aaryn C Mustoe; Jeffrey A French; Thomas F Murray
Journal:  Mol Pharmacol       Date:  2019-02-09       Impact factor: 4.436

Review 6.  Oxytocin structure and function in New World monkeys: from pharmacology to behavior.

Authors:  Aaryn Mustoe; Jack H Taylor; Jeffrey A French
Journal:  Integr Zool       Date:  2018-11       Impact factor: 2.654

Review 7.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

8.  The essential role of Giα2 in prostate cancer cell migration.

Authors:  Miao Zhong; Shineka Clarke; BaoHan T Vo; Shafiq A Khan
Journal:  Mol Cancer Res       Date:  2012-08-30       Impact factor: 5.852

Review 9.  Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.

Authors:  G R Kolar; S M Grote; G L C Yosten
Journal:  J Intern Med       Date:  2016-06-16       Impact factor: 8.989

10.  Oxytocin increases eye gaze in schizophrenia.

Authors:  Ellen R Bradley; Alison Seitz; Andrea N Niles; Katherine P Rankin; Daniel H Mathalon; Aoife O'Donovan; Joshua D Woolley
Journal:  Schizophr Res       Date:  2019-08-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.